Amphotericin B-induced immunosuppression in tumor-bearing mice.
B16 melanoma-bearing mice had a reduced capacity to mount a delayed-type hypersensitivity response, and this response was further depressed when these mice were also treated with multiple daily doses of amphotericin B (AmB). Results from the present experiments, which were designed to simulate the clinical situation, indicate that patients receiving AmB may require frequent monitoring of immune functions during treatment.
D000666:Amphotericin B / Q000494:pharmacology*; D000818:Animals; D000906:Antibodies / Q000276:immunology; D002478:Cells, Cultured; D006968:Hypersensitivity, Delayed / Q000139:chemically induced / Q000276:immunology*; D007165:Immunosuppression Therapy; D008545:Melanoma / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D009181:Mycoses / Q000150:complications; D009374:Neoplasms, Experimental / Q000276:immunology*
D000906:Antibodies; D000666:Amphotericin B